drugset / Trial / NCT05302596

Semaglutide Use in Elderly Obese Patients

NCT05302596

RandomizedParallel-groupOpen-labelTreatment

Summary

This is a single-center, prospective, controlled, randomized and open label study to investigate the effect of the semaglutide addition to standard of care weight loss intervention (personalized lifestyle and exercise) in elderly obese subjects on body weight and body composition as assessed by DEXA.

Timeline

Start
2022-09-01
Primary completion
2023-10-23
Completion
2024-10-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Semaglutide Peptide 1 mg Other

Indications